DEXCOM INC — Director's Dealing 2014

Jul 29, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2014-07-25

Reporting Person: Balo Andrew K (SVP, Regulatory and Clinical)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-07-25	Common Stock	M	10000.0	$8.94	Acquired	169099	Direct
2014-07-25	Common Stock	S	10000.0	$38.1857	Disposed	159099	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-07-25	Non-Qualified Stock Option (right to buy)	$8.94	M	10000.0	Disposed	2017-11-02	Common Stock (10000)	Direct

Footnotes

F1: On November 21, 2013, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $37.91 to $38.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 101,250 unvested restricted stock units, 50,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017, 33,333 of which were granted on March 11, 2013 and shall vest through March 11, 2016, and 17,917 of which were granted on March 8, 2012 and shall vest through March 8, 2015.